NASDAQ:CMPS COMPASS Pathways Q2 2024 Earnings Report $4.04 -0.15 (-3.58%) Closing price 04:00 PM EasternExtended Trading$4.07 +0.03 (+0.62%) As of 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Earnings HistoryForecast COMPASS Pathways EPS ResultsActual EPS-$0.56Consensus EPS -$0.53Beat/MissMissed by -$0.03One Year Ago EPS-$0.62COMPASS Pathways Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ACOMPASS Pathways Announcement DetailsQuarterQ2 2024Date8/1/2024TimeBefore Market OpensConference Call DateThursday, August 1, 2024Conference Call Time8:00AM ETUpcoming EarningsCOMPASS Pathways' Q1 2025 earnings is scheduled for Thursday, May 8, 2025, with a conference call scheduled at 8:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Q1 2025 Earnings ReportConference Call ResourcesConference Call AudioConference Call TranscriptPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by COMPASS Pathways Q2 2024 Earnings Call TranscriptProvided by QuartrAugust 1, 2024 ShareLink copied to clipboard.There are 13 speakers on the call. Operator00:00:00Good day, ladies and gentlemen, and welcome to Compass Pathway's Second Quarter 2024 Conference Call. At this time, all participants are in a listen only mode. As a reminder, this call is being recorded. I would now like to introduce your host for today's call, Stephen Schultz. You may begin. Speaker 100:00:21Welcome all of you and thank you for joining us today for our Q2 20 24 results conference call. Again, my name is Steve Schultz, Senior Vice President of Investor Relations at Compass Pathways. And today, I'm joined by Kabir Nath, our Chief Executive Officer Doctor. Guy Goodwin, our Chief Medical Officer and Terry Luxum, our Chief Financial Officer. The call is being recorded and will be available on the Compass Pathway's Investor Relations website shortly after the conclusion of the call and will be available for a period of 30 days. Speaker 100:00:53Before we begin, let me remind everyone that during the call today, the team will be making forward looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 as amended. You should not place undue reliance on these forward looking statements. Actual events or results could differ materially from those expressed or implied by any forward looking statements as a result of various risks, uncertainties and other factors, including those risks and uncertainties described under the heading Risk Factors in our most recent quarterly report on Form 10 Q filed with the U. S. Securities and Exchange Commission and in subsequent filings made by Compass with the SEC. Speaker 100:01:38Additionally, these forward looking statements represent our views only as of today and should not be relied upon as representing our views as of any subsequent date. We specifically disclaim any obligation to update or revise any forward looking statement, even if our estimates or assumptions change. I'll now hand the call over to Kabir Nath. Speaker 200:02:00Thanks, Steve. Good day, everyone, and thank you for joining us. First, let me welcome 2 new leaders to Compass Pathways. A few weeks ago, we added Laurie Engelbert as Chief Commercial Officer and as you saw just this morning, we have appointed Gino Santini as the new Chairman of our Board of Directors. Laurie and Gino both have strong relevant experience that will benefit COMPASS as we continue to complete our COM360 Phase 3 clinical trials and build our commercial capabilities. Speaker 200:02:35I'm pleased that these exceptional leaders have chosen to be a part of our team, which is a reflection of their commitment to the field of mental health and their confidence in Compass. Turning to our core program in treatment resistant depression, We're doing something that has never been done before at this scale and working with many clinical sites that are new to psilocybin research. We're making progress on recruitment in our COM360 Phase 3 trials. As we discussed on prior quarterly calls, the resources that we added earlier in the year to help accelerate the process of confirming TRD diagnosis have been helpful. We continue to expect the readout for the 6 week primary endpoint top line data from the 5 placebo controlled trial in quarter 4 this year. Speaker 200:03:28However, we're also needing to spend increased time and resources to support clinical sites to recruit as quickly as possible, while maintaining the highest level of quality in the trials. Recruitment is therefore trending towards the end of the year and there's a chance that data could push into January. As a reminder, we expect to need both 5 and 6 for a regulatory submission and we continue to expect the 6 week primary endpoint or 6 by mid-twenty 25. On today's call, Guy will provide some thoughts on key issues that were discussed during the LICOS Adcom and Terry will provide the financial overview. I'll provide some closing comments and we'll then move to Q and A. Speaker 200:04:18Guy? Speaker 300:04:19Thank you, Kabir. The Likos advisory committee was certainly eventful and it provided some key insights into the FDA's thinking and their requirements for review of therapeutics in this new class of drugs. Three items came into focus: the therapy aspect of the clinical protocol, the issue of unblinding and lack of certain safety data that FDA deemed important to understand. Let me discuss these in order. First, regarding psychotherapy, MDMA appears to increase interactive communication with the therapist during the drug experience. Speaker 300:05:03It truly is psychotherapy catalyzed by the drug. This is in contrast with psilocybin, which elicits a subjective inward experience for patients. With COM360, the patient is supported by a licensed therapist or other medical professional mostly for safety purposes. There is no active psychotherapy on the day of drug administration. Most of the administration session is silent and any interaction is typically to redirect the patient's focus back inwards. Speaker 300:05:41Read administration preparation ensures patients understand the trial and what to expect on the day of administration and prepare them to be in the right frame of mind to undergo treatment, not unlike other medical procedures. Patients have 2 post administration sessions to provide them with an opportunity to discuss their experience and integrate it into their lives. 2nd, turning to discussion of unblinding, context is important here. It is not uncommon in neuroscience for drugs to produce effects that are detectable by patients. It is the absence of such effects that unblinds the patients in trial to the psychedelic. Speaker 300:06:29It is the presence of adverse effects like nausea or somnolence that are likely to cue the unblinding that may often occur in other trials. For example, of conventional antidepressants or antipsychotic drugs. Such unblinding has not prevented their approval as medicines. As requested by the FDA, R005 trial is placebo controlled, which will help to characterize a safety baseline, but lack of an active control will make potential unblinding likely. By contrast, our 6 trial was designed similar to the Phase 2b with a strategy to minimize the potential for unblinding. Speaker 300:07:146 has 3 active arms, so patients know that they will receive a dose of COM360, making it more difficult for them to discriminate, in particular between the 10 25 milligram doses. In fact, most participants in the Phase 2b study reported an intensity of psychedelic effects that could have come from any of the doses. In addition, we have also put a cap of 15% on recruitment of patients with prior experience with psychedelic drugs. We believe that this design safeguards the blinding of the trial and the 2 Phase 3 trials together will produce a robust package for the FDA. Finally, we are conducting the COM360 TRD clinical program to the highest standards and we are collecting the range of safety data that would be expected of any pharmaceutical clinical development program including positive side effect data. Speaker 300:08:12For example, we have collected data from the altered states of consciousness questionnaire after every drug administration. This survey is comprised of 94 items covering the full gamut of experiences both positive and negative attributable to psychedelic drugs. Looking at the FDA's guidelines and observing the discussion of the ICOS meeting, we are confident that our pivotal program will deliver what the FDA requires to effectively evaluate COM360 treatment. Let me now hand the call to Terri for the financial overview. Speaker 400:08:47Thank you, Guy. I'll now step through the Q2 financial results. Cash used in operations in the 2nd quarter was $34,400,000 within the guidance range we provided of $32,000,000 to $38,000,000 Regarding Q3 2024 financial guidance, we expect net cash used in operations between $32,000,000 $38,000,000 Turning to full year financial guidance, we expect cash used in operations to be between $110,000,000 $130,000,000 which assumes that we will receive the 2023 R and D tax credit this year. Compass continues to maintain a strong financial position with cash and cash equivalents of $228,600,000 at June 30, 2024. This compares with $262,900,000 at March 31, 2024. Speaker 400:09:45We expect our cash runway to fund operations into 2026. Long term debt under the Hercules loan facility was 29 $400,000 at the end of the Q2. We will continue to manage our cash carefully to advance our pivotal program and to achieve important milestones that we believe will create value for our shareholders. Thank you. And I'll now turn the call back over to Kabir. Speaker 200:10:11Thank you, Terry. While we await the top line data readout for the primary 6 week endpoint in the 5 Phase 3 trial near the end of the Q4, I want to reflect more broadly on our progress. We now have in place a senior management team of seasoned executives who have a passion for treating mental health conditions and decades of relevant collective experience in bringing innovation to patients. We continue to generate all the necessary supporting data for an NDA filing. And our pre commercial collaborations are yielding valuable learnings both for us and for potential future sites of care as we continue our preparations to leverage the commercial delivery network. Speaker 200:10:56The commercial marketplace has seen continued growth for interventional psychiatry treatments such as SPRAVATO, which validates our approach. Finally, I want to thank David Norton for his guidance and commitment to Compass Pathways in serving as Interim Chairman of the Board. And we're pleased that he will continue to serve as a highly valued member of the Board after Gino joins us as Chairman in September. We have a strong team in place to continue to execute our Phase 3 program and build the organization for potential commercialization. With the progress we've made, we're well positioned for continued success in TRD and beyond. Speaker 200:11:39Thank you again for your participation on today's call. I will now turn to Q and A. So I will hand this back to the operator. Operator00:11:47Thank And it comes from the line of Ritu Baral with TD Cowen. Please proceed. Speaker 500:12:09Good morning, guys. Thanks for taking the questions. First question, Kabir, I wanted to just ask about the conduct of ongoing 5. How many DSMB looks have you had? And how is the overall suicidality rate looking just given the high background rate of suicides in the TRD population in general and the focus on this? Speaker 500:12:36Can you give us a sense of conduct? And then I have a couple of follow ups. Thanks. Speaker 200:12:41Sure. Thanks, Rita. And just checking that you can hear us? Yes. Speaker 300:12:45Great. I'll actually hand that first question to Guy, if I may. So Guy? Yes. Hi, Ritu. Speaker 300:12:51We've just recently, as it happened, had a DSMB meeting at which both 5 and 6 were considered and they will be in their quarterly as you may know. Basically the feedback was that we continue the trials as planned, so with no changes to procedures of any kind. Speaker 500:13:14Great. And then another sort of conduct question. One thing that came up in the LICO study, I'm sorry, in the LICOADCOM was the fact that they didn't do labs. And I'm just wondering, I want to make sure I understand the scope of the labs that were requested for that therapy versus, I guess, what we normally think of as labs in biotech, including liver levels, kidney function, etcetera, etcetera. Were there any special labs that the FDA was referring to that they yes, when the discussion focused on the labs? Speaker 300:13:53My understanding and obviously we only kind of got the discussion. We didn't have the background documents so to speak. My understanding was that they were routine labs that they were doing that were not materially different from what is required for other drugs. Speaker 500:14:10Got it. Helpful. And then last question. Have you seen any impact on your enrollment rates either for 5 or 6 based on the ADCOM proceedings? And more specifically, maybe a little more subtly, would you expect just given how much that's been in the news for that to potentially impact your placebo rates such that you might need to take another look at the stats plan or it might change powering? Speaker 500:14:40Thanks so much. Speaker 300:14:43Basically to your last question, no. There's really no suggestion use of issues that were brought up around the use of placebo in general and that form part of the discussion, the background noise if you like that we heard following the AdCom. I mean our sense was that actually there were contending sounds, some were positive, some were trying to in a sense reverse the sentiment that was expressed by the committee. But we haven't really had feedback either from the sites or less directly from patients or in terms of changes in run rates for ourselves that suggest any impact at all. Speaker 500:15:31That's great. Thanks for taking all the questions. Speaker 300:15:34Thanks, Rita. Operator00:15:36Thank you. Our next question comes from the line of Leonid Timashev with RBC Capital Markets. Please proceed. Speaker 600:15:45Thanks. I had maybe one follow-up on I want to brief you his questions and then a second question if that's okay. So I guess just following up on sort of the discussion around the enrollment trends in the sites. I guess can you talk about how sites have been performing? I mean it's something that you alluded to, but I guess with respect to screen in or screen out periods and then I guess any anomalies you may have seen on the blinded data from the raters that might require maybe retraining or spending some of that additional time that you referred to. Speaker 600:16:14I guess, how are you maintaining that site quality? Speaker 200:16:18Yes, I'll start. Thanks, Luneet. So as I said on the call, we are continuing to recruit successfully into both 5 and 6. As we've discussed earlier in the year, the need to actually be better and quicker at getting the TRD diagnosis confirmed and the additional resources we've put in there have been helpful to that. And really it's just a focus on continued quality, ensuring that we do have the right patients, ensuring that sites are doing everything necessary. Speaker 200:16:49We're continuing to be in very close touch with them, visiting them and so on. But I wouldn't say there's anything out of the ordinary or any particular anomalies that we've identified. And certainly no trend breaks post adcom or anything that suggests a change. Speaker 300:17:04Perhaps I'd add, Lynette, that one of the key quality indicators, if you like, for any trial is retention. And that's remained actually better in some ways than we might have expected. So that's reassuring actually for all phases of the trial. You remember there's a first A phase for the primary outcome and then subsequent re dosing and then open label treatment phases. And recruitment has maintained retention has been maintained into indeed the final phase of the trial. Speaker 300:17:32So that has been extremely pleasing. It is of course unblinded in the sense that we don't know what the results are, but we do know that patients are staying in the study and where they not staying in the study that would be a problem of course. Speaker 600:17:46Got it. Thanks. Really helpful. And then just maybe a second question related to the concept of the suicidality. I guess as you've been talking to KOLs, I guess do you have a sense of what might be an acceptable amount of suicidal ideation just given the patient population and the fact that psychiatrists often have some amount of experience managing patients, especially even that SSRIs have some elevated risk that's on the label. Speaker 600:18:14I guess, do you have a sense of what might be an okay signal if one does appear on suicidality? Speaker 300:18:20I think the truth is that clinicians who treat depressed patients simply live with suicidality as a fact of the disorder. It's a core symptom. It's therefore ever present really. And they don't actually think in terms actually that people looking at clinical trial data tend to do. They tend to see it more as a fact of life. Speaker 300:18:42So we don't get the sort of feedback as to what's accept and what is not acceptable. Ultimately, of course, the key observation will be the differential rates if there are any between the different arms of the study. And that will allow us to make a real and genuine conclusion about this risk, hypothetical risk that there may be higher risks in the active arms. We simply at the moment I think don't have sufficient data to say, but we will have that data once we have completed our studies. Operator00:19:19Our next question comes from the line of Charles Duncan with Cantor. Please proceed. Speaker 700:19:26Yes. Good morning, Kabir and team. Thanks for taking our question and good to hear of the progress. Especially like to hear some more from Guy on the recent adcom. But before that, I guess I'm wondering if you can provide a little more granularity on call it the news flow yet this year, understand that the analysis may make December versus January a question mark. Speaker 700:19:57But do you plan to announce the completed enrollment in 5? And then I'll ask another question to Guy. Speaker 200:20:08Thanks, Charles. So we haven't yet determined whether we will make that announcement. Speaker 700:20:14Okay. That would be helpful to hear. Let's moving on to Guy. I guess you did a great job outlining the thoughts post the LICOS AdCom. I'm wondering if there was anything that was surprising to you. Speaker 700:20:31It seems like these are issues that you might have considered, especially given the guidance and design of your trial. And so I guess I'm wondering if there was anything, any new thinking that came out of the ADCOM that perhaps you're doing or were these considerations that you had in designing the 5 and 6 program? Speaker 300:20:58I think speaking for ourselves, there were really no surprises in the AdCom. I mean the tone of the AdCom was surprising as I'm sure anyone listening to it would have agreed at times. But actually in terms of the content, the FDA's contribution, the issues that were discussed, they were not surprising and they were not something that we hadn't to some extent as fully as possible anticipated. Speaker 700:21:26So you don't feel like there was any real change in the FDA's perspective versus the guidance that was put out earlier? Speaker 300:21:39No, we certainly couldn't detect that and we're simply content that our trials are running as they are on track and with all the considerations that we put into designing them. Speaker 200:21:50And I think, Sean, if Speaker 700:21:51I can just add Speaker 200:21:52sorry, if I may just add, I mean referring back also to Ritu's earlier question, I mean, essentially, I think what that showed us was that there's no special consideration or free pass for psychedelic trials. They are expected to be conducted to the same levels of rigor, safety data collection and so on as any other psychiatry trials and that's not a surprise to us. Speaker 700:22:15And probably consistent with the way you do things. Question on 5 versus 6. This may seem like naive, but can you just remind us as to what is the key question that is being asked in those trials? What would you like to see out of those trials to encourage you that you have a drug that's really novel? Speaker 300:22:43Well, that of course is a great question. 5, we would like to see separation from placebo. Other studies have demonstrated that. We would like to do the same. But essentially we would need to continue to demonstrate safety in that study and safety against a placebo baseline. Speaker 300:23:00That's really what it will deliver for us. Our Phase 2 our 6 study will essentially if successful replicate what we saw in 1, the Phase 2 study, which I think was a dramatic demonstration of a dose response effect. And what we would hope to see is whether or not adding a second treatment actually substantially increases remission and response rates. And if that happens that will also be great news for patients. Speaker 200:23:30And then taken together, Charles, it's durability. Clearly, that's a question that we didn't answer in 1 beyond 12 weeks. So that's another key element, particularly out of 6. Speaker 700:23:43Yes. And that durability is of interest to a lot of people and appreciate your good retention comments to the last question. Thanks for taking our questions. Speaker 200:23:54Thanks, Charles. Operator00:23:56Thank you. Our next question comes from the line of Vikram Prouliet with Morgan Stanley. Please proceed. Speaker 800:24:05Hi, good morning. Thank you for taking our questions. We have 2, 1 on the pivotal program in TRD and then 1 on the pipeline. So for 5 and 6, it sounds like near the end of the year and then middle of next year, we'll be getting the 6 week primary endpoint data. But I was curious when the longer term follow-up data from both studies might be communicated publicly? Speaker 800:24:27And then secondly, on the pipeline, could you just remind us where next steps and your thoughts on development plan stands for both PTSD and also potentially bipolar disorder? Thank you. Speaker 200:24:43Thanks, Vikram. So you're right reconfirming those dates that you mentioned for the 6 week primary endpoints. We haven't talked about when we could expect the 26 weeks, but simply projecting the additional 5 to 6 months of data, you can imagine that that's when we would be releasing both of those, but we haven't specifically confirmed that to this point. Regarding PTSD, yes, we continue to believe that that was a very interesting signal that we showed in what was a small open label study. So we are developing some designs and protocols around that. Speaker 200:25:18We're taking external advice also. And as you're aware, though, the current runway does not contemplate an additional study or set of studies in PTSD, but we're continuing to do the work around what that could look like. Speaker 300:25:37Bipolar disorder is obviously remains of great interest to us, but I think it's a rather lower priority at the moment compared to PTSD. Speaker 800:25:47Understood. Thank you. Operator00:25:50Thank you. Our next question comes from the line of Gavin Clark Gartner with Evercore ISI. Please proceed. Speaker 100:26:00Hey, guys. Thanks for taking the questions. First, are you able to see the rates of retreatment in Part B of both of the trials? And is that rate different between the two trials? Speaker 300:26:16In principle, we can see raw rates. We haven't compared them to this point. Speaker 100:26:23Okay. Are you planning to share the overall rates of retreatment at any point prior to the top line and should we also expect that with the top line release? Speaker 300:26:34I don't think so. These are details that we'll obviously make available in due course, but there are considerations around announcing the top line data relating to blinding, which make it important that we don't cause too much interest in the data, for example, from patients themselves. Speaker 100:26:55Got it. And what's the overall rescue rate of rescue therapy use? Where is that tracking in both of the trials? Speaker 300:27:07You mean rescue on the day of administration of the drug? Speaker 100:27:10No, just during the blinded portion of the trial, like starting another medication. Speaker 300:27:15Okay. Yes. Well, I mean that, oh, I see. No, we're not tracking that as a group. I mean essentially, we are blind to the details of the study for obvious reasons. Speaker 100:27:28Got it. Thanks. Operator00:27:31Thanks. One moment for our next question. And it comes from the line of Francois Brisebois with Oppenheimer. Please proceed. Speaker 900:27:41Hi, this is Dan on for Frank. Thanks for taking my question. Just a quick one from us. Regarding the Lycos AdCom, one of the focuses was the challenge of disentangling the contribution of psychotherapy to the efficacy of the drug in Lycos' case. In the case of COMF-five and 6, of course, there's no formal psychotherapy in the trials. Speaker 900:28:05Could you talk about your thoughts regarding the FDA commentary around that? Speaker 300:28:12Yes, I mean my understanding originally was that the FDA had approved the design of the study which of course was placebo versus the doses that were eventually used. And so that they were accepting the idea that a drug could enhance the psychotherapy. I think it introduces complexity, which is what was discussed in the AdCom. But I think frankly we have to wait for what the FDA actually decides. We don't really have clear guidance on what that will be obviously. Speaker 300:28:45We think that we're in a different category. We are not providing a psychotherapy. And so the question of whether a drug versus placebo or one dose versus another is a much simpler decision in terms of deciding efficacy. And I think that's where we rest our current understanding. Operator00:29:06Thank you. Thank you. Our next question comes from the line of Sumant Kulkarni with Canaccord Genuity. Please proceed. Speaker 1000:29:18Hi, thanks for taking our questions. I have 2. So given how important the durability of treatment effect is, especially within the psychedelic therapeutics context, how is COMPASS specifically ensuring that patients don't have any undue use of other treatment modalities or therapeutics post dosing in your Phase III trials because such instances have the potential to obscure durability that could be directly attributable to COM360 treatment? Speaker 300:29:42Yes. I mean, that's a great question. I mean, I think we await to see. We are collecting data about co administration of other drugs throughout the follow-up phase. So we will be able to observationally tell you what the rates are. Speaker 300:29:58Actually actively preventing discouraging patients is obviously difficult. It's simply understood in terms of how the patients give consent, that that's not an objective of the study. But clearly, if there is a clinical need, patients will receive other treatments. And the thing we have to do is to follow what they are and really work out to the extent to which it really is something that is required for the group patients we saw. In the highly responsive patients in 1, we did not see high rates of treatment seeking outside of the trial in up to 12 weeks. Speaker 300:30:34We obviously are going much longer and we will be better informed when we complete the current study. Speaker 200:30:40And just to be clear, I mean, patients do in theory commit to no subsequent use of psychedelics. I mean that is an inclusion criteria and it's part of the informed consent. So clearly we need to monitor that. Speaker 1000:30:53Understood. And the second question is more because investors tend to be hyper focused on the topic of suicidal ideation. So how well studied is this topic when it comes to recreational uses of psilocybin? For example, there was a 2022 paper out of Howard on 400,000 or so U. S. Speaker 1000:31:08Adults that were in the U. S. National Survey of Drug Use that were characterized as lifetime users of MDMA of psilocybin and both psychological distress and suicidal thoughts were found to have reduced odds in that population. Speaker 300:31:22Yes. Well, I couldn't summarize the data better than you just did. I mean that is what the finding is and that of course is why we believe. There are of course slightly smaller studies which are concentrated on prospectively identifying people are going to go and have a psychedelic experience various kinds. And those studies have shown similarly that there tends to be reduction in distress, which is associated with acute use of the drugs, not just lifetime under recreational conditions. Speaker 300:31:52But of course, we are not really very interested in that. We are interested in how we deliver this as an effective treatment for patients in difficult who have experienced difficulties in getting better with other approaches. So our focus is very much more on the clinical experience as you will understand, but it forms useful safety background, I agree. Speaker 1000:32:13Thank you. Operator00:32:15Thank you. Our next question comes from the line of Tom Shrader with BTIG. Please proceed. Speaker 600:32:25Good morning. Thanks for taking Speaker 1100:32:26the questions. I wanted to ask Charles' question in a slightly different way. As we've talked to people about the panel, there was a fair bit of surprise with all the focus on blinding. A lot of people thought the FDA is pretty comfortable with that and you certainly gave a very clean description. Do you agree with that that maybe that wasn't expected? Speaker 300:32:50Well, I think I can only answer whether I expected it. And to be honest, I did expect that to come up because it so frequently comes up when I hear frankly non experts discussing these trials. It is something that a lot of people have got their teeth into and so it's something that people want to discuss. As it may as you may be well aware, it's not an exact science to define what the effect of unblinding is in different studies. And so it's often an argument based on very unsecure basis of in fact, but it's certainly something that gets people's energies up. Speaker 300:33:28And as you see, it certainly caused a lot of energy to be expended in that meeting. Speaker 1100:33:34Hi, quick PTSD follow-up. As we've talked to people, how Speaker 600:33:39derisking do Speaker 1100:33:39you think the PTSD data is on the safety front? People think that the likelihood of a bad experience is much higher in PTSD. So are you confident that you've seen really negative experiences and negotiated your way through them or is 22 patients still too small? Thank you. Speaker 300:34:02I think 22 patients it's still too small. And in addition, they were quite a highly selected group. So these were patients with adult trauma, it excluded people with what is sometimes called developmental trauma, childhood trauma And these people often have had much more difficult lives and much more chronic problems. And some of those patients that sort of patient were in the LICA studies in fact. So we would want to be cautious about how we develop our program and that's why we're going to take advice on it. Speaker 300:34:33But certainly what we saw was very encouraging from an efficacy and a safety perspective. That's all we can say at the moment, but it is undoubtedly for some patients with PTSD, we think this has got high potential. Speaker 1100:34:47Great. Thank you for the answers. Operator00:34:49Thank you. Our next question comes from the line of Elemer Piros with Rodman. Please proceed. Speaker 1200:34:58Yes, good morning. So, Kabir, I think you originally set out to identify and engage 150 sites in 12 different countries. Where do you stand in that with that number? And do you think that you have the right number of sites to complete these two trials? Speaker 200:35:19Yes. Thank you. So that number of sites is across both 5 and 6, and it divides roughly 40, 5 and the remainder in 6. So clearly, 5 and again, as a reminder, 5 is U. S. Speaker 200:35:35Only. So clearly, all those U. S. Sites are up and running in 5. There are some U. Speaker 200:35:44S. Sites up and running already for 6, but a number of the 5 sites will roll into 6 in due course. Ex U. S, we now have sites up and running in the UK, Ireland, Canada, France, Spain, Sweden and some other countries still to come. And I would say we are as we reconfirm the expectation for 6 week endpoint on 6, were exactly in line with where we expected to be in terms of bringing those sites online. Speaker 200:36:16Ultimately, just to push further, it's sometimes asked in 6, we ultimately expect the disposition of patients to be roughly 50% U. S, 50% ex U. S. Speaker 1200:36:28Thank you very much for that detail. And you also have an MDD trial ongoing. Is there a chance that that trial, I think it's roughly 100 patients, would read out before 5? Speaker 300:36:45I don't think that's very likely, Emma. But you never know if it goes if recruitment goes very well, it's possible. But as you know, it's primarily designed to look at PKPD in this population. I mean, it will be of great interest as an MDD study. But it's I think it's unlikely to read out between before 5. Speaker 1200:37:05Thank you very much, Guy. Operator00:37:08Thank you. And as I see no further questions in the queue, I will turn the call back to management for closing remarks. Thank you. Speaker 200:37:17Thank you everyone for participation on today's call. As we said, we continue to make good progress. We are very focused as you can understand on 5 and 6 and continuing to do everything we can to ensure quality execution that we have the right patients in those trials and that we are able to bring forth really robust data at the appropriate time point. So thank you for your participation and look forward to seeing you all in the next quarter. Operator00:37:46And thank you all for participating in today's conference. You may now disconnect.Read morePowered by Conference Call Audio Live Call not available Earnings Conference CallCOMPASS Pathways Q2 202400:00 / 00:00Speed:1x1.25x1.5x2x Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) COMPASS Pathways Earnings HeadlinesAnalysts Set COMPASS Pathways plc (NASDAQ:CMPS) Target Price at $20.20April 27, 2025 | americanbankingnews.comWhy Compass Pathways Stock Was a Double-Digit Winner This WeekApril 25, 2025 | fool.comThink NVDA’s run was epic? You ain’t seen nothin’ yetAsk most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, it surged 239%. And in 2024, it soared another 171% on the year… But what if I told you there was a way to target those types of “peak Nvidia” profit opportunities in 24 hours or less?May 5, 2025 | Timothy Sykes (Ad)Compass Pathways completes dosing in Part A of Phase 3 psilocybin trialApril 23, 2025 | markets.businessinsider.comCompass Pathways Announces Dosing Complete for All Participants in Part A of Phase 3 COMP005 Trial of COMP360 Psilocybin for Treatment-Resistant DepressionApril 22, 2025 | businesswire.comAnalysts Offer Insights on Healthcare Companies: Gilead Sciences (GILD), Argenx Se (ARGX) and COMPASS Pathways (CMPS)April 11, 2025 | markets.businessinsider.comSee More COMPASS Pathways Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like COMPASS Pathways? Sign up for Earnings360's daily newsletter to receive timely earnings updates on COMPASS Pathways and other key companies, straight to your email. Email Address About COMPASS PathwaysCOMPASS Pathways (NASDAQ:CMPS) operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom.View COMPASS Pathways ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Is Reddit Stock a Buy, Sell, or Hold After Earnings Release?Warning or Opportunity After Super Micro Computer's EarningsAmazon Earnings: 2 Reasons to Love It, 1 Reason to Be CautiousRocket Lab Braces for Q1 Earnings Amid Soaring ExpectationsMeta Takes A Bow With Q1 Earnings - Watch For Tariff Impact in Q2Palantir Earnings: 1 Bullish Signal and 1 Area of ConcernVisa Q2 Earnings Top Forecasts, Adds $30B Buyback Plan Upcoming Earnings American Electric Power (5/6/2025)Advanced Micro Devices (5/6/2025)Marriott International (5/6/2025)Constellation Energy (5/6/2025)Arista Networks (5/6/2025)Brookfield Asset Management (5/6/2025)Duke Energy (5/6/2025)Energy Transfer (5/6/2025)Mplx (5/6/2025)Ferrari (5/6/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
There are 13 speakers on the call. Operator00:00:00Good day, ladies and gentlemen, and welcome to Compass Pathway's Second Quarter 2024 Conference Call. At this time, all participants are in a listen only mode. As a reminder, this call is being recorded. I would now like to introduce your host for today's call, Stephen Schultz. You may begin. Speaker 100:00:21Welcome all of you and thank you for joining us today for our Q2 20 24 results conference call. Again, my name is Steve Schultz, Senior Vice President of Investor Relations at Compass Pathways. And today, I'm joined by Kabir Nath, our Chief Executive Officer Doctor. Guy Goodwin, our Chief Medical Officer and Terry Luxum, our Chief Financial Officer. The call is being recorded and will be available on the Compass Pathway's Investor Relations website shortly after the conclusion of the call and will be available for a period of 30 days. Speaker 100:00:53Before we begin, let me remind everyone that during the call today, the team will be making forward looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 as amended. You should not place undue reliance on these forward looking statements. Actual events or results could differ materially from those expressed or implied by any forward looking statements as a result of various risks, uncertainties and other factors, including those risks and uncertainties described under the heading Risk Factors in our most recent quarterly report on Form 10 Q filed with the U. S. Securities and Exchange Commission and in subsequent filings made by Compass with the SEC. Speaker 100:01:38Additionally, these forward looking statements represent our views only as of today and should not be relied upon as representing our views as of any subsequent date. We specifically disclaim any obligation to update or revise any forward looking statement, even if our estimates or assumptions change. I'll now hand the call over to Kabir Nath. Speaker 200:02:00Thanks, Steve. Good day, everyone, and thank you for joining us. First, let me welcome 2 new leaders to Compass Pathways. A few weeks ago, we added Laurie Engelbert as Chief Commercial Officer and as you saw just this morning, we have appointed Gino Santini as the new Chairman of our Board of Directors. Laurie and Gino both have strong relevant experience that will benefit COMPASS as we continue to complete our COM360 Phase 3 clinical trials and build our commercial capabilities. Speaker 200:02:35I'm pleased that these exceptional leaders have chosen to be a part of our team, which is a reflection of their commitment to the field of mental health and their confidence in Compass. Turning to our core program in treatment resistant depression, We're doing something that has never been done before at this scale and working with many clinical sites that are new to psilocybin research. We're making progress on recruitment in our COM360 Phase 3 trials. As we discussed on prior quarterly calls, the resources that we added earlier in the year to help accelerate the process of confirming TRD diagnosis have been helpful. We continue to expect the readout for the 6 week primary endpoint top line data from the 5 placebo controlled trial in quarter 4 this year. Speaker 200:03:28However, we're also needing to spend increased time and resources to support clinical sites to recruit as quickly as possible, while maintaining the highest level of quality in the trials. Recruitment is therefore trending towards the end of the year and there's a chance that data could push into January. As a reminder, we expect to need both 5 and 6 for a regulatory submission and we continue to expect the 6 week primary endpoint or 6 by mid-twenty 25. On today's call, Guy will provide some thoughts on key issues that were discussed during the LICOS Adcom and Terry will provide the financial overview. I'll provide some closing comments and we'll then move to Q and A. Speaker 200:04:18Guy? Speaker 300:04:19Thank you, Kabir. The Likos advisory committee was certainly eventful and it provided some key insights into the FDA's thinking and their requirements for review of therapeutics in this new class of drugs. Three items came into focus: the therapy aspect of the clinical protocol, the issue of unblinding and lack of certain safety data that FDA deemed important to understand. Let me discuss these in order. First, regarding psychotherapy, MDMA appears to increase interactive communication with the therapist during the drug experience. Speaker 300:05:03It truly is psychotherapy catalyzed by the drug. This is in contrast with psilocybin, which elicits a subjective inward experience for patients. With COM360, the patient is supported by a licensed therapist or other medical professional mostly for safety purposes. There is no active psychotherapy on the day of drug administration. Most of the administration session is silent and any interaction is typically to redirect the patient's focus back inwards. Speaker 300:05:41Read administration preparation ensures patients understand the trial and what to expect on the day of administration and prepare them to be in the right frame of mind to undergo treatment, not unlike other medical procedures. Patients have 2 post administration sessions to provide them with an opportunity to discuss their experience and integrate it into their lives. 2nd, turning to discussion of unblinding, context is important here. It is not uncommon in neuroscience for drugs to produce effects that are detectable by patients. It is the absence of such effects that unblinds the patients in trial to the psychedelic. Speaker 300:06:29It is the presence of adverse effects like nausea or somnolence that are likely to cue the unblinding that may often occur in other trials. For example, of conventional antidepressants or antipsychotic drugs. Such unblinding has not prevented their approval as medicines. As requested by the FDA, R005 trial is placebo controlled, which will help to characterize a safety baseline, but lack of an active control will make potential unblinding likely. By contrast, our 6 trial was designed similar to the Phase 2b with a strategy to minimize the potential for unblinding. Speaker 300:07:146 has 3 active arms, so patients know that they will receive a dose of COM360, making it more difficult for them to discriminate, in particular between the 10 25 milligram doses. In fact, most participants in the Phase 2b study reported an intensity of psychedelic effects that could have come from any of the doses. In addition, we have also put a cap of 15% on recruitment of patients with prior experience with psychedelic drugs. We believe that this design safeguards the blinding of the trial and the 2 Phase 3 trials together will produce a robust package for the FDA. Finally, we are conducting the COM360 TRD clinical program to the highest standards and we are collecting the range of safety data that would be expected of any pharmaceutical clinical development program including positive side effect data. Speaker 300:08:12For example, we have collected data from the altered states of consciousness questionnaire after every drug administration. This survey is comprised of 94 items covering the full gamut of experiences both positive and negative attributable to psychedelic drugs. Looking at the FDA's guidelines and observing the discussion of the ICOS meeting, we are confident that our pivotal program will deliver what the FDA requires to effectively evaluate COM360 treatment. Let me now hand the call to Terri for the financial overview. Speaker 400:08:47Thank you, Guy. I'll now step through the Q2 financial results. Cash used in operations in the 2nd quarter was $34,400,000 within the guidance range we provided of $32,000,000 to $38,000,000 Regarding Q3 2024 financial guidance, we expect net cash used in operations between $32,000,000 $38,000,000 Turning to full year financial guidance, we expect cash used in operations to be between $110,000,000 $130,000,000 which assumes that we will receive the 2023 R and D tax credit this year. Compass continues to maintain a strong financial position with cash and cash equivalents of $228,600,000 at June 30, 2024. This compares with $262,900,000 at March 31, 2024. Speaker 400:09:45We expect our cash runway to fund operations into 2026. Long term debt under the Hercules loan facility was 29 $400,000 at the end of the Q2. We will continue to manage our cash carefully to advance our pivotal program and to achieve important milestones that we believe will create value for our shareholders. Thank you. And I'll now turn the call back over to Kabir. Speaker 200:10:11Thank you, Terry. While we await the top line data readout for the primary 6 week endpoint in the 5 Phase 3 trial near the end of the Q4, I want to reflect more broadly on our progress. We now have in place a senior management team of seasoned executives who have a passion for treating mental health conditions and decades of relevant collective experience in bringing innovation to patients. We continue to generate all the necessary supporting data for an NDA filing. And our pre commercial collaborations are yielding valuable learnings both for us and for potential future sites of care as we continue our preparations to leverage the commercial delivery network. Speaker 200:10:56The commercial marketplace has seen continued growth for interventional psychiatry treatments such as SPRAVATO, which validates our approach. Finally, I want to thank David Norton for his guidance and commitment to Compass Pathways in serving as Interim Chairman of the Board. And we're pleased that he will continue to serve as a highly valued member of the Board after Gino joins us as Chairman in September. We have a strong team in place to continue to execute our Phase 3 program and build the organization for potential commercialization. With the progress we've made, we're well positioned for continued success in TRD and beyond. Speaker 200:11:39Thank you again for your participation on today's call. I will now turn to Q and A. So I will hand this back to the operator. Operator00:11:47Thank And it comes from the line of Ritu Baral with TD Cowen. Please proceed. Speaker 500:12:09Good morning, guys. Thanks for taking the questions. First question, Kabir, I wanted to just ask about the conduct of ongoing 5. How many DSMB looks have you had? And how is the overall suicidality rate looking just given the high background rate of suicides in the TRD population in general and the focus on this? Speaker 500:12:36Can you give us a sense of conduct? And then I have a couple of follow ups. Thanks. Speaker 200:12:41Sure. Thanks, Rita. And just checking that you can hear us? Yes. Speaker 300:12:45Great. I'll actually hand that first question to Guy, if I may. So Guy? Yes. Hi, Ritu. Speaker 300:12:51We've just recently, as it happened, had a DSMB meeting at which both 5 and 6 were considered and they will be in their quarterly as you may know. Basically the feedback was that we continue the trials as planned, so with no changes to procedures of any kind. Speaker 500:13:14Great. And then another sort of conduct question. One thing that came up in the LICO study, I'm sorry, in the LICOADCOM was the fact that they didn't do labs. And I'm just wondering, I want to make sure I understand the scope of the labs that were requested for that therapy versus, I guess, what we normally think of as labs in biotech, including liver levels, kidney function, etcetera, etcetera. Were there any special labs that the FDA was referring to that they yes, when the discussion focused on the labs? Speaker 300:13:53My understanding and obviously we only kind of got the discussion. We didn't have the background documents so to speak. My understanding was that they were routine labs that they were doing that were not materially different from what is required for other drugs. Speaker 500:14:10Got it. Helpful. And then last question. Have you seen any impact on your enrollment rates either for 5 or 6 based on the ADCOM proceedings? And more specifically, maybe a little more subtly, would you expect just given how much that's been in the news for that to potentially impact your placebo rates such that you might need to take another look at the stats plan or it might change powering? Speaker 500:14:40Thanks so much. Speaker 300:14:43Basically to your last question, no. There's really no suggestion use of issues that were brought up around the use of placebo in general and that form part of the discussion, the background noise if you like that we heard following the AdCom. I mean our sense was that actually there were contending sounds, some were positive, some were trying to in a sense reverse the sentiment that was expressed by the committee. But we haven't really had feedback either from the sites or less directly from patients or in terms of changes in run rates for ourselves that suggest any impact at all. Speaker 500:15:31That's great. Thanks for taking all the questions. Speaker 300:15:34Thanks, Rita. Operator00:15:36Thank you. Our next question comes from the line of Leonid Timashev with RBC Capital Markets. Please proceed. Speaker 600:15:45Thanks. I had maybe one follow-up on I want to brief you his questions and then a second question if that's okay. So I guess just following up on sort of the discussion around the enrollment trends in the sites. I guess can you talk about how sites have been performing? I mean it's something that you alluded to, but I guess with respect to screen in or screen out periods and then I guess any anomalies you may have seen on the blinded data from the raters that might require maybe retraining or spending some of that additional time that you referred to. Speaker 600:16:14I guess, how are you maintaining that site quality? Speaker 200:16:18Yes, I'll start. Thanks, Luneet. So as I said on the call, we are continuing to recruit successfully into both 5 and 6. As we've discussed earlier in the year, the need to actually be better and quicker at getting the TRD diagnosis confirmed and the additional resources we've put in there have been helpful to that. And really it's just a focus on continued quality, ensuring that we do have the right patients, ensuring that sites are doing everything necessary. Speaker 200:16:49We're continuing to be in very close touch with them, visiting them and so on. But I wouldn't say there's anything out of the ordinary or any particular anomalies that we've identified. And certainly no trend breaks post adcom or anything that suggests a change. Speaker 300:17:04Perhaps I'd add, Lynette, that one of the key quality indicators, if you like, for any trial is retention. And that's remained actually better in some ways than we might have expected. So that's reassuring actually for all phases of the trial. You remember there's a first A phase for the primary outcome and then subsequent re dosing and then open label treatment phases. And recruitment has maintained retention has been maintained into indeed the final phase of the trial. Speaker 300:17:32So that has been extremely pleasing. It is of course unblinded in the sense that we don't know what the results are, but we do know that patients are staying in the study and where they not staying in the study that would be a problem of course. Speaker 600:17:46Got it. Thanks. Really helpful. And then just maybe a second question related to the concept of the suicidality. I guess as you've been talking to KOLs, I guess do you have a sense of what might be an acceptable amount of suicidal ideation just given the patient population and the fact that psychiatrists often have some amount of experience managing patients, especially even that SSRIs have some elevated risk that's on the label. Speaker 600:18:14I guess, do you have a sense of what might be an okay signal if one does appear on suicidality? Speaker 300:18:20I think the truth is that clinicians who treat depressed patients simply live with suicidality as a fact of the disorder. It's a core symptom. It's therefore ever present really. And they don't actually think in terms actually that people looking at clinical trial data tend to do. They tend to see it more as a fact of life. Speaker 300:18:42So we don't get the sort of feedback as to what's accept and what is not acceptable. Ultimately, of course, the key observation will be the differential rates if there are any between the different arms of the study. And that will allow us to make a real and genuine conclusion about this risk, hypothetical risk that there may be higher risks in the active arms. We simply at the moment I think don't have sufficient data to say, but we will have that data once we have completed our studies. Operator00:19:19Our next question comes from the line of Charles Duncan with Cantor. Please proceed. Speaker 700:19:26Yes. Good morning, Kabir and team. Thanks for taking our question and good to hear of the progress. Especially like to hear some more from Guy on the recent adcom. But before that, I guess I'm wondering if you can provide a little more granularity on call it the news flow yet this year, understand that the analysis may make December versus January a question mark. Speaker 700:19:57But do you plan to announce the completed enrollment in 5? And then I'll ask another question to Guy. Speaker 200:20:08Thanks, Charles. So we haven't yet determined whether we will make that announcement. Speaker 700:20:14Okay. That would be helpful to hear. Let's moving on to Guy. I guess you did a great job outlining the thoughts post the LICOS AdCom. I'm wondering if there was anything that was surprising to you. Speaker 700:20:31It seems like these are issues that you might have considered, especially given the guidance and design of your trial. And so I guess I'm wondering if there was anything, any new thinking that came out of the ADCOM that perhaps you're doing or were these considerations that you had in designing the 5 and 6 program? Speaker 300:20:58I think speaking for ourselves, there were really no surprises in the AdCom. I mean the tone of the AdCom was surprising as I'm sure anyone listening to it would have agreed at times. But actually in terms of the content, the FDA's contribution, the issues that were discussed, they were not surprising and they were not something that we hadn't to some extent as fully as possible anticipated. Speaker 700:21:26So you don't feel like there was any real change in the FDA's perspective versus the guidance that was put out earlier? Speaker 300:21:39No, we certainly couldn't detect that and we're simply content that our trials are running as they are on track and with all the considerations that we put into designing them. Speaker 200:21:50And I think, Sean, if Speaker 700:21:51I can just add Speaker 200:21:52sorry, if I may just add, I mean referring back also to Ritu's earlier question, I mean, essentially, I think what that showed us was that there's no special consideration or free pass for psychedelic trials. They are expected to be conducted to the same levels of rigor, safety data collection and so on as any other psychiatry trials and that's not a surprise to us. Speaker 700:22:15And probably consistent with the way you do things. Question on 5 versus 6. This may seem like naive, but can you just remind us as to what is the key question that is being asked in those trials? What would you like to see out of those trials to encourage you that you have a drug that's really novel? Speaker 300:22:43Well, that of course is a great question. 5, we would like to see separation from placebo. Other studies have demonstrated that. We would like to do the same. But essentially we would need to continue to demonstrate safety in that study and safety against a placebo baseline. Speaker 300:23:00That's really what it will deliver for us. Our Phase 2 our 6 study will essentially if successful replicate what we saw in 1, the Phase 2 study, which I think was a dramatic demonstration of a dose response effect. And what we would hope to see is whether or not adding a second treatment actually substantially increases remission and response rates. And if that happens that will also be great news for patients. Speaker 200:23:30And then taken together, Charles, it's durability. Clearly, that's a question that we didn't answer in 1 beyond 12 weeks. So that's another key element, particularly out of 6. Speaker 700:23:43Yes. And that durability is of interest to a lot of people and appreciate your good retention comments to the last question. Thanks for taking our questions. Speaker 200:23:54Thanks, Charles. Operator00:23:56Thank you. Our next question comes from the line of Vikram Prouliet with Morgan Stanley. Please proceed. Speaker 800:24:05Hi, good morning. Thank you for taking our questions. We have 2, 1 on the pivotal program in TRD and then 1 on the pipeline. So for 5 and 6, it sounds like near the end of the year and then middle of next year, we'll be getting the 6 week primary endpoint data. But I was curious when the longer term follow-up data from both studies might be communicated publicly? Speaker 800:24:27And then secondly, on the pipeline, could you just remind us where next steps and your thoughts on development plan stands for both PTSD and also potentially bipolar disorder? Thank you. Speaker 200:24:43Thanks, Vikram. So you're right reconfirming those dates that you mentioned for the 6 week primary endpoints. We haven't talked about when we could expect the 26 weeks, but simply projecting the additional 5 to 6 months of data, you can imagine that that's when we would be releasing both of those, but we haven't specifically confirmed that to this point. Regarding PTSD, yes, we continue to believe that that was a very interesting signal that we showed in what was a small open label study. So we are developing some designs and protocols around that. Speaker 200:25:18We're taking external advice also. And as you're aware, though, the current runway does not contemplate an additional study or set of studies in PTSD, but we're continuing to do the work around what that could look like. Speaker 300:25:37Bipolar disorder is obviously remains of great interest to us, but I think it's a rather lower priority at the moment compared to PTSD. Speaker 800:25:47Understood. Thank you. Operator00:25:50Thank you. Our next question comes from the line of Gavin Clark Gartner with Evercore ISI. Please proceed. Speaker 100:26:00Hey, guys. Thanks for taking the questions. First, are you able to see the rates of retreatment in Part B of both of the trials? And is that rate different between the two trials? Speaker 300:26:16In principle, we can see raw rates. We haven't compared them to this point. Speaker 100:26:23Okay. Are you planning to share the overall rates of retreatment at any point prior to the top line and should we also expect that with the top line release? Speaker 300:26:34I don't think so. These are details that we'll obviously make available in due course, but there are considerations around announcing the top line data relating to blinding, which make it important that we don't cause too much interest in the data, for example, from patients themselves. Speaker 100:26:55Got it. And what's the overall rescue rate of rescue therapy use? Where is that tracking in both of the trials? Speaker 300:27:07You mean rescue on the day of administration of the drug? Speaker 100:27:10No, just during the blinded portion of the trial, like starting another medication. Speaker 300:27:15Okay. Yes. Well, I mean that, oh, I see. No, we're not tracking that as a group. I mean essentially, we are blind to the details of the study for obvious reasons. Speaker 100:27:28Got it. Thanks. Operator00:27:31Thanks. One moment for our next question. And it comes from the line of Francois Brisebois with Oppenheimer. Please proceed. Speaker 900:27:41Hi, this is Dan on for Frank. Thanks for taking my question. Just a quick one from us. Regarding the Lycos AdCom, one of the focuses was the challenge of disentangling the contribution of psychotherapy to the efficacy of the drug in Lycos' case. In the case of COMF-five and 6, of course, there's no formal psychotherapy in the trials. Speaker 900:28:05Could you talk about your thoughts regarding the FDA commentary around that? Speaker 300:28:12Yes, I mean my understanding originally was that the FDA had approved the design of the study which of course was placebo versus the doses that were eventually used. And so that they were accepting the idea that a drug could enhance the psychotherapy. I think it introduces complexity, which is what was discussed in the AdCom. But I think frankly we have to wait for what the FDA actually decides. We don't really have clear guidance on what that will be obviously. Speaker 300:28:45We think that we're in a different category. We are not providing a psychotherapy. And so the question of whether a drug versus placebo or one dose versus another is a much simpler decision in terms of deciding efficacy. And I think that's where we rest our current understanding. Operator00:29:06Thank you. Thank you. Our next question comes from the line of Sumant Kulkarni with Canaccord Genuity. Please proceed. Speaker 1000:29:18Hi, thanks for taking our questions. I have 2. So given how important the durability of treatment effect is, especially within the psychedelic therapeutics context, how is COMPASS specifically ensuring that patients don't have any undue use of other treatment modalities or therapeutics post dosing in your Phase III trials because such instances have the potential to obscure durability that could be directly attributable to COM360 treatment? Speaker 300:29:42Yes. I mean, that's a great question. I mean, I think we await to see. We are collecting data about co administration of other drugs throughout the follow-up phase. So we will be able to observationally tell you what the rates are. Speaker 300:29:58Actually actively preventing discouraging patients is obviously difficult. It's simply understood in terms of how the patients give consent, that that's not an objective of the study. But clearly, if there is a clinical need, patients will receive other treatments. And the thing we have to do is to follow what they are and really work out to the extent to which it really is something that is required for the group patients we saw. In the highly responsive patients in 1, we did not see high rates of treatment seeking outside of the trial in up to 12 weeks. Speaker 300:30:34We obviously are going much longer and we will be better informed when we complete the current study. Speaker 200:30:40And just to be clear, I mean, patients do in theory commit to no subsequent use of psychedelics. I mean that is an inclusion criteria and it's part of the informed consent. So clearly we need to monitor that. Speaker 1000:30:53Understood. And the second question is more because investors tend to be hyper focused on the topic of suicidal ideation. So how well studied is this topic when it comes to recreational uses of psilocybin? For example, there was a 2022 paper out of Howard on 400,000 or so U. S. Speaker 1000:31:08Adults that were in the U. S. National Survey of Drug Use that were characterized as lifetime users of MDMA of psilocybin and both psychological distress and suicidal thoughts were found to have reduced odds in that population. Speaker 300:31:22Yes. Well, I couldn't summarize the data better than you just did. I mean that is what the finding is and that of course is why we believe. There are of course slightly smaller studies which are concentrated on prospectively identifying people are going to go and have a psychedelic experience various kinds. And those studies have shown similarly that there tends to be reduction in distress, which is associated with acute use of the drugs, not just lifetime under recreational conditions. Speaker 300:31:52But of course, we are not really very interested in that. We are interested in how we deliver this as an effective treatment for patients in difficult who have experienced difficulties in getting better with other approaches. So our focus is very much more on the clinical experience as you will understand, but it forms useful safety background, I agree. Speaker 1000:32:13Thank you. Operator00:32:15Thank you. Our next question comes from the line of Tom Shrader with BTIG. Please proceed. Speaker 600:32:25Good morning. Thanks for taking Speaker 1100:32:26the questions. I wanted to ask Charles' question in a slightly different way. As we've talked to people about the panel, there was a fair bit of surprise with all the focus on blinding. A lot of people thought the FDA is pretty comfortable with that and you certainly gave a very clean description. Do you agree with that that maybe that wasn't expected? Speaker 300:32:50Well, I think I can only answer whether I expected it. And to be honest, I did expect that to come up because it so frequently comes up when I hear frankly non experts discussing these trials. It is something that a lot of people have got their teeth into and so it's something that people want to discuss. As it may as you may be well aware, it's not an exact science to define what the effect of unblinding is in different studies. And so it's often an argument based on very unsecure basis of in fact, but it's certainly something that gets people's energies up. Speaker 300:33:28And as you see, it certainly caused a lot of energy to be expended in that meeting. Speaker 1100:33:34Hi, quick PTSD follow-up. As we've talked to people, how Speaker 600:33:39derisking do Speaker 1100:33:39you think the PTSD data is on the safety front? People think that the likelihood of a bad experience is much higher in PTSD. So are you confident that you've seen really negative experiences and negotiated your way through them or is 22 patients still too small? Thank you. Speaker 300:34:02I think 22 patients it's still too small. And in addition, they were quite a highly selected group. So these were patients with adult trauma, it excluded people with what is sometimes called developmental trauma, childhood trauma And these people often have had much more difficult lives and much more chronic problems. And some of those patients that sort of patient were in the LICA studies in fact. So we would want to be cautious about how we develop our program and that's why we're going to take advice on it. Speaker 300:34:33But certainly what we saw was very encouraging from an efficacy and a safety perspective. That's all we can say at the moment, but it is undoubtedly for some patients with PTSD, we think this has got high potential. Speaker 1100:34:47Great. Thank you for the answers. Operator00:34:49Thank you. Our next question comes from the line of Elemer Piros with Rodman. Please proceed. Speaker 1200:34:58Yes, good morning. So, Kabir, I think you originally set out to identify and engage 150 sites in 12 different countries. Where do you stand in that with that number? And do you think that you have the right number of sites to complete these two trials? Speaker 200:35:19Yes. Thank you. So that number of sites is across both 5 and 6, and it divides roughly 40, 5 and the remainder in 6. So clearly, 5 and again, as a reminder, 5 is U. S. Speaker 200:35:35Only. So clearly, all those U. S. Sites are up and running in 5. There are some U. Speaker 200:35:44S. Sites up and running already for 6, but a number of the 5 sites will roll into 6 in due course. Ex U. S, we now have sites up and running in the UK, Ireland, Canada, France, Spain, Sweden and some other countries still to come. And I would say we are as we reconfirm the expectation for 6 week endpoint on 6, were exactly in line with where we expected to be in terms of bringing those sites online. Speaker 200:36:16Ultimately, just to push further, it's sometimes asked in 6, we ultimately expect the disposition of patients to be roughly 50% U. S, 50% ex U. S. Speaker 1200:36:28Thank you very much for that detail. And you also have an MDD trial ongoing. Is there a chance that that trial, I think it's roughly 100 patients, would read out before 5? Speaker 300:36:45I don't think that's very likely, Emma. But you never know if it goes if recruitment goes very well, it's possible. But as you know, it's primarily designed to look at PKPD in this population. I mean, it will be of great interest as an MDD study. But it's I think it's unlikely to read out between before 5. Speaker 1200:37:05Thank you very much, Guy. Operator00:37:08Thank you. And as I see no further questions in the queue, I will turn the call back to management for closing remarks. Thank you. Speaker 200:37:17Thank you everyone for participation on today's call. As we said, we continue to make good progress. We are very focused as you can understand on 5 and 6 and continuing to do everything we can to ensure quality execution that we have the right patients in those trials and that we are able to bring forth really robust data at the appropriate time point. So thank you for your participation and look forward to seeing you all in the next quarter. Operator00:37:46And thank you all for participating in today's conference. You may now disconnect.Read morePowered by